Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Rohto Pharmaceutical Co ( (JP:4527) ).
Rohto Pharmaceutical Co. has revised its dividend plan for the fiscal year ending March 31, 2026, raising the forecast year-end dividend from ¥23 to ¥25 per share and lifting the total annual dividend from ¥44 to ¥46. This follows an interim dividend of ¥21 and compares with a total payout of ¥36 in the previous fiscal year, underscoring a steady increase in shareholder distributions.
Management said the decision reflects recent business performance trends and an earnings outlook that supports higher returns to investors while maintaining its fundamental policy of dividends linked to operating results. The move signals confidence in the company’s financial health and is likely to bolster its appeal to income-focused shareholders in the pharmaceutical and consumer health sector.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2980.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. is a Japan-based healthcare company listed on the TSE Prime that develops and sells pharmaceutical and consumer health products. The company focuses on stable profit generation and emphasizes shareholder returns as a core management priority within the broader pharmaceuticals and healthcare industry.
Average Trading Volume: 809,337
Technical Sentiment Signal: Sell
Current Market Cap: Yen537.9B
Find detailed analytics on 4527 stock on TipRanks’ Stock Analysis page.